U.S. Federal Trade Commission, 2004-05-25: FTC case record stating that Bristol-Myers Squibb made improper Orange Book listings and paid a would-be competitor more than $70 million to delay a generic, concerning Taxol, Platinol and BuSpar; the consent order stripped BMS of 30-month stays on later-listed patents.
The complaint alleged that BMS purposely made wrongful listings in the Orange Book of the U.S. Food & Drug Administration and that it also paid a potential competitor over $70 million to delay the entry of its generic drug.
HTML page, unpaginated
U.S. Federal Trade Commission, 2004-05-25: FTC case record stating that Bristol-Myers Squibb made improper Orange Book listings and paid a would-be competitor more than $70 million to delay a generic, concerning Taxol, Platinol and BuSpar; the consent order stripped BMS of 30-month stays on later-listed patents. Funder/conflicts: n/a (government enforcement record). Maker: Bristol-Myers Squibb. Comparator: n/a. This is the primary record for generic-delay conduct involving Taxol; it concerns Orange Book listing abuse and a payoff, not a composition-of-matter patent on paclitaxel. Docket C-4076, file 0110046, last updated 25 May 2004. Study type: regulatory record.
